|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001792,
umls-concept:C0010181,
umls-concept:C0026336,
umls-concept:C0030705,
umls-concept:C0085155,
umls-concept:C0332128,
umls-concept:C0344315,
umls-concept:C0360105,
umls-concept:C0684321,
umls-concept:C0814225,
umls-concept:C0815327,
umls-concept:C1524063,
umls-concept:C1550548,
umls-concept:C1555714,
umls-concept:C1705654
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2007-9-24
|
|
pubmed:abstractText |
Since their invention in the late 1980s and early 1990s, selective serotonin reuptake inhibitors (SSRIs) have become the primary form of pharmaceutical treatment for depression. As the patents of several top-selling SSRIs have expired or are soon to be expired, the SSRI market is expected to witness an increasing share of generic SSRIs. We explored the impact of generic drug entry on the cost effectiveness of SSRIs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
T
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1170-7690
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
843-62
|
|
pubmed:meshHeading |
pubmed-meshheading:17887806-Aged,
pubmed-meshheading:17887806-Aged, 80 and over,
pubmed-meshheading:17887806-Algorithms,
pubmed-meshheading:17887806-Bayes Theorem,
pubmed-meshheading:17887806-Citalopram,
pubmed-meshheading:17887806-Cost-Benefit Analysis,
pubmed-meshheading:17887806-Depression,
pubmed-meshheading:17887806-Drugs, Generic,
pubmed-meshheading:17887806-Female,
pubmed-meshheading:17887806-Fluoxetine,
pubmed-meshheading:17887806-Humans,
pubmed-meshheading:17887806-Male,
pubmed-meshheading:17887806-Medicare,
pubmed-meshheading:17887806-Models, Statistical,
pubmed-meshheading:17887806-Paroxetine,
pubmed-meshheading:17887806-Regression Analysis,
pubmed-meshheading:17887806-Serotonin Uptake Inhibitors,
pubmed-meshheading:17887806-Sertraline,
pubmed-meshheading:17887806-Treatment Outcome,
pubmed-meshheading:17887806-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
|
|
pubmed:affiliation |
Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. yashih@mdanderson.org
|
|
pubmed:publicationType |
Journal Article
|
